Your account is not claimed yet. You can sign up with ORCID to claim your account.

Daniel V LaBarbera

ORCID

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 7

Top Venues

Journal of medicinal chemistry

Oncogene

Proceedings of the National Academy of Sciences of the United States of America

SLAS discovery : advancing life sciences R & D

Arizona State University (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Arizona State University Aug 1o 2001 - May 12o 2005

United States

PHD :: Chemistry and Biochemistry

Publications

Brett J Prigaro, Hector Esquer, Qiong Zhou, Laura A Pike, Paul Awolade, Xin-He Lai, Adedoyin D Abraham, Joshua M Abbott, Brock Matter, Uday B Kompella, Wells A Messersmith, Daniel L Gustafson, Daniel V LaBarbera
Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. Journal of medicinal chemistry 65 (5) (2022)
Neeraj Agarwal, Sebastien Rinaldetti, Bassem B Cheikh, Qiong Zhou, Evan P Hass, Robert T Jones, Molishree Joshi, Daniel V LaBarbera, Simon R V Knott, Thomas R Cech, Dan Theodorescu
TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer. Proceedings of the National Academy of Sciences of the United States of America 118 (38) (2021)
Hector Esquer, Qiong Zhou, Travis Nemkov, Adedoyin D Abraham, Sébastien Rinaldetti, Yu-Chi Chen, Xiaohu Zhang, Michael V Orman, Angelo D'Alessandro, Marc Ferrer, Wells A Messersmith, Daniel V LaBarbera
Isolating and targeting the real-time plasticity and malignant properties of epithelial-mesenchymal transition in cancer. Oncogene 40 (16) (2021)
Joshua M Abbott, Qiong Zhou, Hector Esquer, Laura Pike, Travis P Broneske, Sébastien Rinaldetti, Adedoyin D Abraham, Dominique A Ramirez, Paul J Lunghofer, Todd M Pitts, Daniel P Regan, Aik Choon Tan, Daniel L Gustafson, Wells A Messersmith, Daniel V LaBarbera
First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. Molecular cancer therapeutics 19 (8) (2020)
Hector Esquer, Qiong Zhou, Adedoyin D Abraham, Daniel V LaBarbera
Advanced High-Content-Screening Applications of Clonogenicity in Cancer. SLAS discovery : advancing life sciences R & D 25 (7) (2020)
Adedoyin D Abraham, Hector Esquer, Qiong Zhou, Nicholas Tomlinson, Brayden D Hamill, Joshua M Abbott, Linfeng Li, Laura A Pike, Sébastien Rinaldetti, Dominique A Ramirez, Paul J Lunghofer, Jose D Gomez, Jerome Schaack, Travis Nemkov, Angelo D'Alessandro, Kirk C Hansen, Daniel L Gustafson, Wells A Messersmith, Daniel V LaBarbera
Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer. Journal of medicinal chemistry 62 (22) (2019)
Bharat Bashyal, Linfeng Li, Trpta Bains, Anjan Debnath, Daniel V LaBarbera
Larrea tridentata: A novel source for anti-parasitic agents active against Entamoeba histolytica, Giardia lamblia and Naegleria fowleri. PLoS neglected tropical diseases 11 (8) (2017)

Daniel V LaBarbera.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Daniel V LaBarbera